|
|
 |
|
Viewing report
|
|
|
|
Lung Cancer Therapeutics Market Outlook and Pipeline Analysis
Arrowhead Publishers, Nov 2009
With over 50% of all non-small cell lung cancer (NSCLC) patients diagnosed at the advanced stages of the disease, and 95% of all small-cell lung cancer (SCLC) patients unsuitable for surgical resection, drug therapy plays a vital role in the management of lung cancer. Such high level of unmet need ensures the lung cancer market is an attractive commercial opportunity for new drug development.
Lung Cancer Therapeutics Market & Pipeline Analysis supports the process of successful product development and commercialization within the
pharmaceutical/biopharmaceutical lung cancer market by addressing the following key areas:
- Epidemiology of lung cancer
- Current lung cancer treatments
- Analysis of current lung cancer therapeutics
- Unmet needs within the lung cancer market
- Research and development (R&D) approaches towards lung cancer
- Pipeline analysis of key lung cancer candidates
- Forecast sales of key pipeline lung cancer candidates
The report also analyzes the market status and potential for the following key lung cancer therapies:
- Sanofi-Aventis’ Taxotere (docetaxel)
- Eli-Lilly’s Gemzar (gemcitabine)
- Eli-Lilly’s Alimta (pemetrexed)
- GlaxoSmithKline’s Hycamtin (topotecan) (SCLC therapeutic)
- OSI Pharmaceuticals/Roche’s Tarceva (erlotinib)
- AstraZeneca’s Iressa (gefitinib)
- Roche’s Avastin (bevazicumab)
and the market potential for the following key late-clinical stage developmental candidates:
- Opaxio
- Erbitux (line extensions)
- Zactima
- Picoplatin
This in-depth, quality report delivers:
- An assessment of the lung market potential, including identification of unmet needs, commercial opportunities, and key trends in R&D
- Analysis of the lung cancer pipeline with in-depth clinical and commercial assessment of key Phase III candidates
- Seven major pharmaceutical market sales forecasts to 2015 for key pipeline candidates incorporating product events
Report highlights include:
- The author has identified 70 drugs in the late-stage lung cancer pipeline. Collectively, key late-phase products have a forecast sales potential of up to $5651m by 2015 in the seven major pharmaceutical markets.
- Molecular targeted therapies (MTTs) are the focus of R&D in lung cancer. Of the MTTs in late-phase development, Erbitux (cetuximab; ImClone /Bristol-Myers Squibb/Merck KGaA) is forecast to achieve the highest level of sales, with $1000m by 2015.
- The author forecasts AstraZeneca’s Iressa (gefitinib) will overcome its disappointing start in the NSCLC arena following positive results of two recent Phase III trials. Iressa will go on to compete well with Roche’s Avastin and OSI Pharma/Roche’s Tarceva (erlotinib).
Purchasing this report will enable you to:
- Assess opportunities and risks influencing R&D in lung cancer, unmet needs in the treatment of the disease, and trends in current development
- Identify key lung cancer products in late-phase development based on sales forecasts to 2015 to maximize your product’s commercial potential
- Gain an impartial perspective of the strategies used between competing companies involved in the lung cancer pipeline to enhance your product’s performance
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Lung Cancer Therapeutics Market (NSCLC & SCLC) - 2010-2020 (Pipeline Assessment and Market Forecast) in G7 countries.
The Global Cancer Vaccine Market, 2nd Edition: Pipeline Analysis and Future Market Impact
Cancer Therapeutics - Market Insight and R&D Pipeline Analysis
Pipeline Insight: Cancer Overview - Lung, Brain, Head and Neck, Thyroid
Cancer Drug Discoveries: What the Future Holds: Non-Small Cell Lung Cancer Chapter
Lung Cancer Therapeutics - Global Strategic Business Report
Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Pipeline Insight: Lung Cancers Overview - Intensive R&D activity but little improvement in patient outcomes
Cancer Therapeutics 2006: Market Dynamics and R&D Trends
Pipeline Insight: Non-Small Cell Lung Cancer - Pipeline Set To Offer Only Modest Improvements
|
|
|
|
